Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
08:00am, Wednesday, 29'th Nov 2023
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
09:00am, Thursday, 02'nd Nov 2023
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –
Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor
05:03pm, Tuesday, 15'th Aug 2023
Cogent Biosciences, Inc. is developing the lead asset bezuclastinib, a KIT inhibitor, in various indications. The company has demonstrated positive clinical data for bezuclastinib in advanced systemic
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
08:00am, Tuesday, 08'th Aug 2023
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
11:23am, Friday, 07'th Jul 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
08:00am, Wednesday, 12'th Apr 2023
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defin
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
02:17am, Tuesday, 28'th Feb 2023
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising t
Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
07:02pm, Tuesday, 27'th Dec 2022
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define
Cogent Biosciences: What's Ahead
01:16pm, Tuesday, 13'th Sep 2022
Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has address
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
11:35am, Tuesday, 12'th Jul 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questio
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
12:02pm, Monday, 13'th Jun 2022
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
